参考文献1. McMahan ZH, Tucker AE, Perin J, et al. Relationship between gastrointestinal transit, Medsger Gastrointestinal Severity, and University of California–Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 symptoms in patients with systemic sclerosis. Arthritis Care Res (Hoboken). 2022 Mar;74(3):442–450.2. Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum. 1994 Sep;37(9):1265–12823. Shreiner AB, Murray C, Denton C, et al. Gastrointestinal manifestations of systemic sclerosis. J Scleroderma Relat Disord. 2016;1(3):247–256.4. Vigone B, Caronni M, Severino A, et al. Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: Results from the open label cross-over PROGASS study. Arthritis Res Ther. 2017 Jun 20;19(1):145.5. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 1991;325(21):1461–1467.6. Dein E, Kuo PL, Hong YS, et al. Evaluation of risk factors for pseudo-obstruction in systemic sclerosis. Semin Arthritis Rheum. 2019 Dec;49(3):405–410.7. Ahuja NK, Mische L, Clarke JO, et al. Pyridostigmine for the treatment of gastrointestinal symptoms in systemic sclerosis. Semin Arthritis Rheum. 2018 Aug;48(1):111–116. 来源于中华临床免疫和变态反应杂志，陈智勇编译 好书推荐，点击链接了解详情：